NCT03716427View on ClinicalTrials.gov

Drug Interaction Study of CT1812 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 10, 2016

Primary Completion Date

December 27, 2016

Study Completion Date

February 15, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

CT1812

DRUG

tolbutamide

Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of tolbutamide

DRUG

dextromethorphan

Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of dextromethorphan

DRUG

Omeprazole

Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of omeprazole

DRUG

midazolam

Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of midazolam

Trial Locations (1)

49007

Jasper Clinic, Kalamazoo

Sponsors
All Listed Sponsors
lead

Cognition Therapeutics

INDUSTRY

NCT03716427 - Drug Interaction Study of CT1812 in Healthy Volunteers | Biotech Hunter | Biotech Hunter